Nichi-Iko Pharmaceutical Co., Ltd. provided consolidated earnings guidance for the second quarter and full year of fiscal ending March 31, 2022. For the second quarter, the company expects revenue of ¥94,000 million, Operating loss of ¥5,200 million, loss attributable to owners of parent of ¥5,300 million, Basic loss per share were ¥82.61. For the year, the company expects revenue of ¥195,000 million, Operating profit of ¥500 million, Profit attributable to owners of parent of ¥200 million, Basic earnings per share of ¥3.12.